Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes

British Journal of Clinical Pharmacology

Volumn 51, Issue 5, 2001, Pages 461-470

  Yeo, Karen Rowland ^a,b   Yeo, Wilfred W ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

CYP3A4; Diltiazem; Interaction; Simvastatin; Verapamil

Indexed keywords

CYTOCHROME P450 INHIBITOR; DILTIAZEM; DRUG METABOLITE; MIBEFRADIL; SIMVASTATIN; TESTOSTERONE; VERAPAMIL;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG METABOLISM; DRUG POTENCY; ENZYME ASSAY; ENZYME INACTIVATION; ENZYME KINETICS; ENZYME SUBSTRATE; HUMAN; HUMAN TISSUE; IC 50; IN VIVO STUDY; INCUBATION TIME; INHIBITION KINETICS; LIVER MICROSOME; PRIORITY JOURNAL;

CALCIUM CHANNEL BLOCKERS; CYTOCHROME P-450 ENZYME SYSTEM; DILTIAZEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICROSOMES, LIVER; SIMVASTATIN; VERAPAMIL;

EID: 0034854303     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2001.01386.x     Document Type: Article

References (29)

1. Randomised trial of cholesterol lowering in 4444 patients with heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. Comparison of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
3. Drug-interaction-induced rhabdomyolysis
4. Rhabdomyolysis due to interaction of simvastatin with mibefradil
5. FDA announce new drug-interacting warnings for mibefradil
6. In vitro metabolism of simvastatin in humans - Identification of metabolising enzymes and effect of the drug on hepatic P450s
7. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: An in vitro investigation with human liver preparations
8. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin
9. Calcium channel blocker-simvastatin interaction
10. In vitro and in vivo drug interactions involving human CYP3A
11. The interaction of diltiazem with lovastatin and pravastatin
12. Erythromycin and verapamil considerably increase simvastatin and simvastatin acid concentrations
13. Role of CYP3A4 in human hepatic diltiazem N-demethylation: Inhibition of CYP3A4 activity by oxidised diltiazem metabolites
14. Diltiazem inhibition of cytochrome P450, 3A activity is due to metabolite-intermediate complex formation
15. Drug interactions with calcium channel blockers: Possible involvement of metabolite-intermediate complexation with CYP3A
16. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation in human liver microsomes
17. Protein measurement with the folin phenol reagent
18. Mechanism-based inactivation of cytochrome P4503A4 by mifepristone (RU486)
19. In vitro and in vivo biotransformation of simvastatin, an inhibitor Of HMG-Coa Reductase
20. Potent and selective inactivation of human liver microsomal cytochrome P450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor
21. Mechanism-based inactivation of human liver microsomal cytochrome P450 III A4 by gestodene
22. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
23. Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients
24. Atorvastatin pharmacokinetic interactions with other CYP3A4 substrates: Erythromycin and ethinyl estradiol
25. Influence of erythromycin pre- and co-treatment on the single dose pharmacokinetics of cerivastatin
26. Clinical pharmacokinetics of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors
27. Lipid-lowering for prevention of coronary heart disease: What policy now?